Thus, there seems to be an interesting crosstalk of EGFR-TGF-β and PD-1 which could be further explored in head and neck cancers and other cancer types treated with anti-EGFR or pembrolizumab alone [123]. This evidence concerns the gene TGFB1 and cancer.